EQL Pharma's Mellozzan (melatonin) tablets now available from pharmacies in Sweden

Lund, March 22, 2021. EQL Pharma today announces that the company's Mellozzan (melatonin in tablet form) is now available in pharmacies in Sweden. Mellozzan, which is a prescription-only drug and used for treating insomnia in children with ADHD where other so-called sleep hygiene measures have been insufficient, is available at doses of 1 mg, 2 mg, 3 mg, 4 mg and 5 mg. Mellozzan is also used as a short-term treatment for jet lag in adults.

"We are pleased that Mellozzan is now available in Swedish pharmacies", says Christer Fåhraeus, CEO of EQL Pharma. "In order to get reimbursement for Mellozzan we have recently submitted an application to the Swedish Dental and Pharmaceutical Benefits Agency (TLV). Such a decision may take weeks or months".

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 17 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 10 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.